RNS Reach Story
Go to market news section View chart   Print
Oxford BioDynamics PLC   -  OBD   

Queen's Award for Enterprise

Released 07:00 23-Apr-2019

RNS Number : 7154W
Oxford BioDynamics PLC
23 April 2019
 

23 April 2019

 

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

Oxford BioDynamics receives Queen's Award for Enterprise

 

·     The Queen's Award for Enterprise is the UK's highest accolade for business success

·     OBD honoured with the award for Enterprise in Innovation for its EpiSwitch™ platform

 

Oxford BioDynamics Plc is delighted to announce that it has today been recognised as a winner of the 2019 Queen's Award for Enterprise, the most prestigious enterprise award given to UK businesses. The Company has been granted the Queen's Award for Enterprise in Innovation, demonstrating the outstanding performance and commercial success of OBD's proprietary technology platform, EpiSwitch™, based on the latest advances in regulatory genome architecture and its functional links to patient stratifications and outcomes in oncology, neurodegenerative, inflammatory, metabolic and other indications.

 

EpiSwitch™ is an innovative technology platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as "chromosome conformation signatures". These biomarker signatures can provide a compelling, stable framework from which changes in the regulation of a genome can be analysed, long before the results of these epigenetic changes manifest themselves as obvious abnormalities.

 

Validated EpiSwitch™ biomarker applications have demonstrated high efficacy in predictive, prognostic and diagnostic patient stratifications for lung, haematological, prostate, thyroid and skin cancers, as well as in rheumatoid arthritis, and amyotrophic lateral sclerosis. Baseline predictive stratifications by EpiSwitch™ for response to immune-checkpoint inhibitors are excellent surrogates for standard primary endpoints used in clinical trials, such as progression free survival. The Company has recently entered into its fifth collaboration agreement with a leading pharmaceutical company for the development of predictive biomarkers for immuno-oncology therapeutics. To date, EpiSwitch™ has been used to develop biomarkers on more than 6,500 blood samples in over 140 diverse projects.

 

The EpiSwitchTM platform is designed to accelerate drug discovery and development processes, improve success rates of therapeutic candidates, and reduce the overall cost of therapeutic development and health-care infrastructure by enabling precision medicine initiatives and empowering informed clinical decision-making.

 

Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:

 

"We are delighted to have been chosen for such a prestigious award, which is an outstanding achievement for the Company. This award is recognised worldwide as a standard of enterprise excellence, reflecting the hard work and commitment shown by our team over the years in developing real-world solutions to unmet clinical needs of high priority. I'd like to extend my thanks to everyone at OBD for their part in this achievement.

 

The award is a wonderful recognition of the value OBD and its EpiSwitch™ platform has generated, but also an acknowledgement of the innovative environment at the University of Oxford, from where OBD was spun-out. Together, we are helping to bring critical solutions onto the world stage."

 

-ENDS-

 

For further details please contact:

 

Oxford BioDynamics Plc

Christian Hoyer Millar, CEO

Paul Stockdale, CFO

 

+44 (0)1865 518910

FTI Consulting

Financial Public Relations Adviser

Brett Pollard

Natalie Garland-Collins

+44 (0)20 3727 1000

 

Notes for Editors

 

About the Queen's Awards for Enterprise

 

The Queen's Awards for Enterprise are awarded for outstanding achievement by UK businesses in the categories of: innovation, international trade, sustainable development and promoting opportunity through social mobility.

 

The awards are made annually by Her Majesty The Queen and are given for the highest levels of excellence demonstrated in each category. Winners of The Queen's Awards can expect an invitation to attend a special reception at Buckingham Palace.

 

To find out more about the awards visit the Queen's Award website: https://queensawards.blog.gov.uk/

 

 

About Oxford BioDynamics Plc

 

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

 

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

 

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRADBGDSUUDBGCD
Close


London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

 


Queen's Award for Enterprise - RNS